Baby KJ’s CRISPR Treatment: The Unknown Cost and the Challenge of Treating More Patients

KJ Muldoon’s treatment showed that a CRISPR-based medicine can be designed for one child’s mutation and delivered in months. It did not establish what such care would cost at scale—or even a publicly documented manufacturing cost for KJ’s own doses. His early clinical progress is promising, but the durability and full extent of the benefit are still unknown. 91112

What did KJ’s treatment cost?

No verified manufacturing bill for KJ’s therapy appears in the provided reporting. The widely repeated $2 million figure is an example of what developing an initial individualized treatment might cost. A related suggestion that a later treatment could cost $100,000 assumes that components and development work can be reused. Neither number is a measured manufacturing cost for KJ, an established price for another patient, or a reimbursement rate. 610

That distinction matters: designing and testing a new editor, making clinical-grade material, and manufacturing a dose are related expenses, but they are not interchangeable. A treatment built for one person cannot spread its development costs across a conventional market of patients. 611

How did the base-editing therapy work?

KJ was born with severe CPS1 deficiency, a disorder that prevents his body from adequately clearing ammonia generated when it processes protein. His team designed a guide RNA for his particular genetic variant and used lipid nanoparticles to deliver it alongside instructions for a CRISPR base editor. The aim was to change a DNA letter in liver cells, rather than replace the entire gene. 11213

The published clinical report describes two infusions, given at approximately seven and eight months of age. Subsequent public accounts describe a third dose; the difference reflects the timing of the reports, not two different treatments. In the seven weeks after the first infusion, KJ tolerated more dietary protein and a reduction in an ammonia-lowering medication, with no serious adverse events reported in that initial study. Its authors cautioned that longer follow-up was needed. 41214

How is KJ doing more than a year later?

KJ received his first infusion in February 2025. A year later, Children’s Hospital of Philadelphia marked his continued progress, and later reporting said he was doing well. Those updates are encouraging, but they do not establish that CPS1 deficiency has been cured or that the effect will last indefinitely. Continued follow-up is needed to assess lasting benefit and potential delayed harms. 391112

What would make one-patient therapies repeatable?

The proposed strategy is a platform: keep as much of the editor, delivery method, manufacturing process and testing approach consistent as possible, while changing the guide that targets each patient’s mutation. That could reduce repeated development work, but each variation still has to be made reliably and checked for quality and unintended edits. The projected savings are a goal, not a demonstrated cost curve. 68

Regulation is another bottleneck. A large, separate trial for every rare mutation may be impractical. Under the FDA’s proposed plausible mechanism approach, developers could assemble evidence across related individualized treatments instead of treating every variant as an entirely unrelated drug. The proposal does not dispense with evidence of safety and effectiveness: developers still need a credible connection between the genetic change, the treatment’s action and patient outcomes. 237

Finally, a repeatable process is not automatically a reimbursable one. Insurers would need a defensible price and evidence of benefit, particularly when long-term outcomes remain uncertain. Shared evidence standards and sustained outcome tracking could help make coverage decisions—and potentially outcomes-linked payments—more workable. For now, KJ’s case demonstrates clinical possibility, not a proven business or payment model for one-patient editors. 711